Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
In April, acting Attorney General Todd Blanche signed an order that formally moved state-approved medical marijuana products from Schedule I to Schedule III.
Simplified Text
In April 2026, acting Attorney General Todd Blanche signed an order formally moving state-approved medical marijuana products from Schedule I to Schedule III.
Confidence Score
1.000
Claim Maker
The author
Context Type
News Article
Context Details
{
    "date": "2026-04",
    "drug": "medical marijuana",
    "role": "acting Attorney General",
    "person": "Todd Blanche",
    "to_schedule": "Schedule III",
    "from_schedule": "Schedule I"
}
Subject Tags
Policy Todd Blanche Attorney General Drug Scheduling Medical Marijuana
UUID
4f42316a-a6c3-4f52-b1b3-58e6b05c02cc
Vector Index
✗ No vector
Created
September 30, 2026 at 5:01 AM (2 weeks ago)
Last Updated
September 30, 2026 at 5:01 AM (2 weeks ago)

Original Sources for this Claim (2)

All source submissions that originally contained this claim.

Screenshot of https://reason.com/2026/09/29/the-way-the-fda-and-dea-ban-drugs-is-unaccountable-and-arbitrary
The Way the FDA and DEA Ban Drugs Is Unaccountable and Arbitrary
Completed Analysis
13 claims 🔥
2 weeks ago
https://reason.com/2026/09/29/the-way-the-fda-and-dea-ban-drugs-is-unaccountable-and-arbitrary

A new Government Accountability Office (GAO) report reveals that the FDA and DEA lack clear policies and procedures for drug scheduling decisions. This arbitrary process impacts research and has contributed to the failures of the war on drugs.

Drug Policy DEA FDA Government Accountability Office Controlled Substances Act Drug Scheduling Marijuana Legalization Bureaucracy
Screenshot of https://reason.com/2026/09/30/hazy-federal-criteria-for-classifying-drugs-invite-arbitrary-bureaucratic-judgments
Hazy Drug Classification Criteria Invite Dubious Bureaucratic Judgments
Completed Analysis
10 claims 🔥
1 week ago
https://reason.com/2026/09/30/hazy-federal-criteria-for-classifying-drugs-invite-arbitrary-bureaucratic-judgments

A GAO report notes that the Controlled Substances Act (CSA) does not define "potential for abuse" or "accepted medical use," leading to arbitrary bureaucratic judgments. This lack of clarity has significant criminal justice implications, as seen in the historical treatment of cannabis.

Drug Policy Controlled Substances Act Drug Classification Government Accountability Office DEA FDA Cannabis Reclassification

Similar Claims (5)

Other claims identified as semantically similar to this one.